SLC5A2 and chronic kidney disease: We discussed the novel treatment options that have been recently introduced in the context prevention of CKD progression in type 2 diabetes, namely Glucagon-like peptide-1 (GLP-1) receptor agonist, sodium–glucose co-transporter 2 (SGLT2) inhibitors [24], and finerenone, a non-steroidal mineralocorticoid receptor antagonist [25].